Enanta Pharmaceuticals
ENTA
117 hedge funds and large institutions have $380M invested in Enanta Pharmaceuticals in 2015 Q1 according to their latest regulatory filings, with 31 funds opening new positions, 47 increasing their positions, 29 reducing their positions, and 38 closing their positions.
62% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 29
6% less funds holding
Funds holding: 124 → 117 (-7)
18% less first-time investments, than exits
New positions opened: 31 | Existing positions closed: 38
31% less capital invested
Capital invested by funds: $549M → $380M (-$170M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
65% less call options, than puts
Call options by funds: $430K | Put options by funds: $1.24M
Top Buyers
| 1 |
ACM
Apex Capital Management
Dayton,
Ohio
|
+$20.1M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$18.8M |
| 3 |
MVM
McClain Value Management
New Canaan,
Connecticut
|
+$17.3M |
| 4 |
KAM
Krensavage Asset Management
New York
|
+$16.5M |
| 5 |
Millennium Management
New York
|
+$10M |
Top Sellers
ENTA Hedge Fund Activity: Q1 2015 in Review
117 of the 3,752 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q1 2015, worth a combined $380M — down 31% from $549M a quarter earlier.
Sellers outnumbered buyers: 38 funds closed out of ENTA and 31 opened new positions — a net loss of 7 holders — while 29 trimmed existing stakes and 47 added.
The largest buyer was Apex Capital Management, adding an estimated $20.1M. The largest seller was Fidelity Investments, cutting an estimated $30.2M.
- 117 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q1 2015, down from 124 in Q4 2014.
- Funds reported $380M of Enanta Pharmaceuticals stock for Q1 2015, down 31% quarter-over-quarter.
- 31 funds opened new Enanta Pharmaceuticals positions in Q1 2015 and 38 closed out, a net change of -7 holders.
- The largest Enanta Pharmaceuticals buyer in Q1 2015 was Apex Capital Management, an estimated $20.1M added.
- The largest Enanta Pharmaceuticals seller in Q1 2015 was Fidelity Investments, an estimated $30.2M sold.
Based on aggregated 13F filings for Q1 2015.